Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2025-01-12 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
TLX to Acquire Next-Gen Therapeutics and Biologics Platform 5 pages 238.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the acquisition of next-generation therapeutic assets and a biologics technology platform from ImaginAb, Inc. It details the transaction terms, purchase price, milestone payments, and equity considerations. The content focuses on a corporate transaction involving asset purchase and technology licensing, including financial terms and strategic rationale. There are no financial statements, quarterly or annual results, nor is this a transcript, proxy, or governance document. The document is a formal announcement of a capital transaction (acquisition) and financing arrangement (equity issuance as part of consideration). Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-01-12 English
Presentation to Accompany Biologics Platform Acquisition 14 pages 1.0MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Telix Pharmaceuticals about the acquisition of a novel biologics technology platform and therapeutic assets. It includes transaction details, technology descriptions, pipeline information, and preclinical data. The text references an ASX announcement and Form 20-F filings but does not itself contain full financial statements or regulatory filings. The content is structured as a comprehensive investor presentation focusing on strategic business developments, technology, and pipeline, typical of investor presentations rather than formal regulatory filings or financial reports. The length (15,000 characters) and detailed content support classification as an Investor Presentation (IP).
2025-01-12 English
Proposed issue of securities - TLX 6 pages 22.3KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX announcement format used for the proposed issue of securities. It details the number and type of securities to be issued, the consideration for the securities, the proposed issue date, and compliance with ASX listing rules. The content focuses on a placement or other type of issue of shares and performance rights related to an acquisition. There are no financial statements or comprehensive financial performance data included, nor is this a report or presentation. It is clearly an announcement regarding capital raising and securities issuance. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2025-01-12 English
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue 4 pages 187.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 13 January 2025 providing a quarterly business update for Telix Pharmaceuticals Limited for the quarter ended 31 December 2024 (Q4 2024). It includes unaudited revenue figures, operational highlights, clinical trial progress, regulatory updates, and corporate milestones. The document is not a full financial report but rather a commercial and operational performance update for a quarter. It does not contain detailed financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR). It also does not fit into categories like Earnings Release (ER) because it provides more detailed business updates beyond key financial highlights. The document is a quarterly business update announcement, which aligns best with the Interim / Quarterly Report (IR) category as it covers substantive financial data and analysis for a period shorter than a full fiscal year, including unaudited revenue and operational progress. Therefore, the appropriate classification is IR with high confidence.
2025-01-12 English
Telix JP Morgan Healthcare Conference 2025 Presentation 33 pages 4.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Telix Pharmaceuticals Limited, containing extensive information about the company's products, clinical trials, financial performance (including FY2024 revenue guidance), strategic roadmap, and near-term catalysts. It includes forward-looking statements, market opportunity data, and pipeline details. The document is approximately 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The content is focused on investor information, strategy, and financial highlights rather than a formal regulatory filing or standalone financial report. There is no indication that this is an earnings release (which would be shorter and focused on key financial results), nor is it a full annual or interim report with detailed financial statements. The presence of forward-looking statements, commercial performance, and strategic outlook aligns with an Investor Presentation. Therefore, the most appropriate classification is Investor Presentation (IP).
2025-01-12 English
Notification of cessation of securities - TLX 4 pages 15.5KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of conditional rights to securities for Telix Pharmaceuticals Limited. It provides specific information about securities that have ceased, including dates and reasons for cessation, and updates on issued capital following these changes. The document is a formal announcement to the ASX about changes in the company's securities, specifically the cessation of certain share rights and appreciation rights. This type of announcement fits the category of a Major Shareholding Notification or related securities change notification. However, since it specifically reports cessation of securities (lapse of rights) rather than shareholding threshold changes, it aligns best with the category for notifications about changes in significant share ownership or securities status. Given the options, the closest and most appropriate classification is Major Shareholding Notification (MRQ). The document is not a full financial report, earnings release, or management report, nor is it a proxy or governance document. It is a regulatory announcement about securities status changes.
2025-01-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.